Actively Recruiting
Rifampin-combined Antibiotic Therapy for Staphylococcal PJI
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2025-12-31
428
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, multicenter, randomized controlled study. Patients were evaluated through inclusion and exclusion criteria. Patients who meet the conditions will sign an informed consent form. After DAIR surgery, they will be treated with intravenous antibiotics for 1-2 weeks and then randomly assigned to one of the following two groups: Antibiotic treatment group: All enrolled patients will be treated with antibiotics (fluoroquinolones or linezolid) for 3 months based on the results of microbial culture and drug sensitivity after surgery. Rifampicin combined with antibiotics treatment group: In addition to the above-mentioned antibiotics, all enrolled patients were treated with rifampicin for 3 months after the operation. The infection control rates of the two groups were judged through at least 2-year follow-up after the operation.The study will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting parallel group randomised trials. Ethical approval will be obtained from each institution. Written informed consent will be obtained from all participants to ensure their voluntary participation and understanding of the study.
CONDITIONS
Official Title
Rifampin-combined Antibiotic Therapy for Staphylococcal PJI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with periprosthetic joint infection according to MSIS criteria
- Pathogenic bacteria identified as Staphylococcus by microbial culture and drug sensitivity tests
- Complete clinical data available
- Age under 80 years old without serious complications or immunosuppressive status
- Willing and physically and mentally able to participate in the study and tests
- Signed informed consent and ethics committee approval obtained
You will not qualify if you...
- Presence of chronic inflammation in other parts of the body before surgery
- Infection caused by non-staphylococcal bacteria or mixed infection
- Other diseases affecting outcome such as immune deficiency or liver and kidney dysfunction
- Expected lifespan less than six months
- Determined by researcher to no longer meet study criteria due to compliance issues
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Actively Recruiting
Research Team
X
Xinyu Fang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here